• 1
    Hammond E, McKinnon E, Nolan D. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Clin Infect Dis 2010; 51: 591599.
  • 2
    Duran S, Savès M, Spire B et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001; 15: 24412444.
  • 3
    Mallal SA, John M, Moore CB et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 13091316.
  • 4
    Benn P, Sauret-Jackson V, Cartledge J et al. Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors. HIV Med 2009; 10: 351355.
  • 5
    Martin A, Smith DE, Carr A et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18: 10291036.
  • 6
    Mallon PW, Miller J, Kovacic JC et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men – a randomized, placebo-controlled study. AIDS 2006; 20: 10031010.
  • 7
    Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis 2010; 10: 183.
  • 8
    Calmy A, Bloch M, Wand H et al. No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial. HIV Med 2010; 11: 493501.
  • 9
    Guaraldi G, Fontdevila J, Christensen LH et al. Surgical correction of HIV-associated facial lipoatrophy. AIDS 2011; 25: 112.
  • 10
    Sturm LP, Cooter RD, Mutimer KL, Graham JC, Maddern GJ. A systematic review of permanent and semipermanent dermal fillers for HIV-associated facial lipoatrophy. AIDS Patient Care STDS 2009; 23: 699714.
  • 11
    Fuller J. A 39-year-old man with HIV-associated lipodystrophy. JAMA 2008; 300: 10561066.
  • 12
    Levy RM, Redbord KP, Hanke CW. Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study. J Am Acad Dermatol 2008; 59: 923933.
  • 13
    Carey D, Baker D, Petoumenos K et al. Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up. HIV Med 2009; 10: 163172.
  • 14
    Lafaurie M, Dolivo M, Porcher R, Rudant J, Madelaine I, Molina J-M. Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J Acquir Immune Defic Syndr 2005; 38: 393398.
  • 15
    Negredo E, Higueras C, Adell X et al. Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances. AIDS Patient Care STDS 2006; 20: 829837.
  • 16
    Moyle GJ, Brown S, Lysakova L, Barton SE. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med 2006; 7: 181185.
  • 17
    Negredo E, Puig J, Aldea D et al. Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy. AIDS Res Hum Retroviruses 2009; 25: 451455.
  • 18
    Orlando G, Guaraldi G, De Fazio D et al. Long-term psychometric outcomes of facial lipoatrophy therapy: forty-eight-week observational, nonrandomized study. AIDS Patient Care STDS 2007; 21: 833842.
  • 19
    Mole B, Gillaizeau F, Carbonnel E et al. Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: results of the LIPOPHILL open-label study. AIDS Res Hum Retroviruses 2012; 28: 251258.
  • 20
    De Santis G, Jacob V, Baccarani A et al. Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: a 2-year clinical experience. Plas. Reconst. Surg 2008; 121: 644653.
  • 21
    Guaraldi G, Orlando G, De Fazio D et al. Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study. Antivir Ther 2005; 10: 753759.
  • 22
    Padilla S, Gallego JA, Masiá M, Gutiérrez F. Single-slice computed tomography and anthropometric skinfold analysis for evaluation of facial lipoatrophy in HIV-infected patients. Clin Infect Dis 2004; 39: 18481851.
  • 23
    Clayson DJ, Wild DJ, Quarterman P, Duprat-Lomon I, Kubin M, Coons SJ. A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials. Pharmacoeconomics 2006; 24: 751765.
  • 24
    Carr A, Law M, HIV Lipodystrophy Case Definition Study Group. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 2003; 33: 571576.
  • 25
    James J, Carruthers A, Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg 2002; 28: 979986.
  • 26
    Valantin MA, Aubron-Olivier C, Ghosn J et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003; 17: 24712477.
  • 27
    Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 2005; 52: 233239.
  • 28
    Cattelan AM, Bauer U, Trevenzoli M et al. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy. Arch Dermatol 2006; 142: 329334.
  • 29
    Hanke CW, Redbord KP. Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging. J Drugs Dermatol 2007; 6: 123128.
  • 30
    Engelhard P, Humble G, Mest D. Safety of Sculptra: a review of clinical trial data. J Cosmet Laser Ther 2005; 7: 201205.
  • 31
    Rauso R, Freda N, Parlato V, Gherardini G, Amore R, Tartaro G. Polyacrylamide gel injection for treatment of human immunodeficiency virus-associated facial lipoatrophy: 18 months follow-up. Dermatol Surg 2011; 37: 15841589.
  • 32
    Mansor S, Breiting VB, Dahlstrøm K, Andersen AB, Andersen O, Christensen LH. Polyacrylamide gel treatment of antiretroviral therapy-induced facial lipoatrophy in HIV patients. Aesthetic Plast Surg 2011; 35: 709716.
  • 33
    Pallua N, Wolter TP. A 5-year assessment of safety and aesthetic results after facial soft-tissue augmentation with polyacrylamide hydrogel (Aquamid): a prospective multicenter study of 251 patients. Plast Reconstr Surg 2010; 125: 17971804.
  • 34
    Liu HL, Cheung WY. Complications of polyacrylamide hydrogel (PAAG) injection in facial augmentation. J Plast Reconstr Aesthet Surg 2010; 63: e912.
  • 35
    Alijotas-Reig J, Garcia-Gimenez V. Adverse reactions caused by different filler injections in the same region. J Eur Acad Dermatol Venereol 2011; 25: 736737.
  • 36
    Ono S, Ogawa R, Hyakusoku H. Complications after polyacrylamide hydrogel injection for soft-tissue augmentation. Plast Reconstr Surg 2010; 126: 13491357.
  • 37
    Chrastil-LaTowsky B, Wesley NO, MacGregor JL, Kaminer MS, Arndt KA. Delayed inflammatory reaction to bio-alcamid polyacrylamide gel used for soft-tissue augmentation. Arch Dermatol 2009; 145: 13091312.